Short Interest in CDT Equity Inc. (NASDAQ:CDT) Increases By 326.9%

by · The Cerbat Gem

CDT Equity Inc. (NASDAQ:CDT – Get Free Report) was the target of a significant increase in short interest during the month of June. As of June 30th, there was short interest totaling 167,688 shares, an increase of 326.9% from the June 15th total of 39,284 shares. Based on an average daily trading volume, of 36,828,063 shares, the short-interest ratio is currently 0.0 days. Currently, 3.9% of the shares of the company are short sold.

CDT Equity Stock Performance

Shares of NASDAQ CDT traded down $0.03 during trading on Friday, hitting $0.38. The company had a trading volume of 211,716 shares, compared to its average volume of 18,995,698. CDT Equity has a 12 month low of $0.38 and a 12 month high of $492.00. The firm has a market capitalization of $1.85 million, a P/E ratio of -0.00 and a beta of 1.49. The stock has a 50 day simple moving average of $1.06 and a 200 day simple moving average of $13.60.

CDT Equity (NASDAQ:CDT – Get Free Report) last announced its quarterly earnings data on Wednesday, April 15th. The company reported $695.11 earnings per share (EPS) for the quarter.

Analyst Ratings Changes

Several brokerages have recently weighed in on CDT. Wall Street Zen cut shares of CDT Equity to a “strong sell” rating in a research note on Saturday, June 27th. Weiss Ratings restated a “sell (e+)” rating on shares of CDT Equity in a research note on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, CDT Equity has a consensus rating of “Sell”.

Get Our Latest Stock Report on CDT

CDT Equity Company Profile

(Get Free Report)

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.

Featured Stories